A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy

NANot yet recruitingINTERVENTIONAL
Enrollment

236

Participants

Timeline

Start Date

November 30, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2028

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Induction chemotherapy plus Concurrent chemotherapy

"Induction chemotherapy: TP( Docetaxel 75mg/m2, D1 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles) OR GP (Gemcitabine 1000mg/m2,D1,D8 and cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles)~Concurrent chemotherapy: DDP -- Cisplatin 25 mg/m2, D1-3 , every 3 weeks for 2 cycles during radiation."

DRUG

Concurrent chemotherapy

Concurrent chemotherapy: DDP -- Cisplatin 25 mg/m2, D1-3 , every 3 weeks for 2 cycles during radiation.

RADIATION

IMRT

Radical radiation: Intensity-modulated radiotherapy

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
collaborator

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

OTHER

collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

collaborator

Fifth Affiliated Hospital, Sun Yat-Sen University

OTHER

collaborator

First People's Hospital of Foshan

OTHER

lead

Sun Yat-sen University

OTHER

NCT05622474 - A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy | Biotech Hunter | Biotech Hunter